Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic

 
• By Joseph Haas, Beth Allan, Deanna Kamienski, and Maureen Riordan

Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.

Tech Transfer regular column feature image

Continuing a collaborative research agreement signed in 2016, Neon Therapeutics licensed technology from the [Netherlands Cancer Institute] (NKI) that will enable it to advance its personalized neoantigen T-cell therapy candidate NEO-PTC-01 into clinical development.

The agreement announced Oct. 4 grants the Cambridge, Mass.-based biotech exclusive intellectual property rights for an ex vivo induction platform...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.